You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to use to the funds to accelerate the commercialization of its CRISPRclean technology and expand into additional markets.
Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.
The molecular assay detects and differentiates Trichomonas vaginalis and/or Mycoplasma genitalium in clinical urine samples.
The firm's whole-genome amplification chemistry may help researchers better understand cancer heterogeneity, even between cells.
The reagent is used for the detection of cytokeratin 19 mRNA in surgically removed sentinel lymph nodes in order to diagnose lymph node metastasis.
The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
The St. Louis-based firm will use the funds to develop its colorectal cancer screening test, which measures eukaryotic RNA isolated from epithelial cells in stool.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.